One target is the human trophoblastic cell surface antigen-2 (TROP2) which is overexpressed in a proportion of all breast cancer types, including over 80% of TNBC cases.26,27 These increased levels are correlated with a worse prognosis in breast cancer patients.28,29 In 2021, sacituzumab govitecan-hziy (Trodelvy), a TROP2 antibody-drug conjugant (ADC) was approved for use in TNBC. Here, TACSTD2 is linked to breast carcinoma.